Oncology Therapeutic Drug Monitoring Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Oncology Therapeutic Drug Monitoring Market: Monoclonal Antibody Type (Infliximab (IFX), Adalimumab (ADL), Vedolizumab (VDL), Ustekinumab (UTK), Golimumab (GLM), Etanercept (ETN), Rituximab (RTX), Tocilizumab (TCZ)), Technology Type (Immunoassay, Others) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Oncology Therapeutic Drug Monitoring Market size is valued at USD x million in 2021 and is expected to reach a value of USD x million by 2028, growing at a CAGR of x% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Oncology Therapeutic Drug Monitoring Market and that can be segmented by monoclonal antibody type, and technology type. By monoclonal antibody type, the Oncology Therapeutic Drug Monitoring Market has been segmented into infliximab (IFX), adalimumab (ADL), vedolizumab (VDL), ustekinumab (UTK), golimumab (GLM), Etanercept (ETN), rituximab (RTX), tocilizumab (TCZ)). The golimumab (GLM)segment is likely to be the largest and fastest-growing segment in terms of monoclonal antibody type. Based on technology type, the Oncology Therapeutic Drug Monitoring Market is segmented into immunoassay and others.  Among these, the immunoassay segment is expected to have the fastest-growing market during the forecast period 2022-2028.

Key Developments:

In July 2021, Roche announced the approval of “Ronapreve” (casirivimab and indevimab) for intravenous infusion treatment of patients with mild to moderate COVID-19. Under Article 14-3 of the Pharmaceuticals and Medical Devices Act, the antibody combination received Special Approval.

Oncology Therapeutic Drug Monitoring Market

MARKET SUMMARY
-
X
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– X%
  • Largest Market– North America

Oncology Therapeutic Drug

Monitoring Market

  • Oncology Therapeutic Drug Monitoring Market report gives a comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • Oncology Therapeutic Drug Monitoring Market is segmented based on monoclonal antibody type, technology type and Geography.
Market Leaders
  • Grifols, S.A.
  • Miraca Life Sciences
  • Prometheus Laboratories Inc.
  • R-biopharm
  • BÜHLMANN
Oncology Therapeutic Drug Monitoring Market

Drivers and Restraints

The market has been growing due to the rising demand for monoclonal antibodies (mABs) as a result of the COVID-19 pandemic. The Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for three monoclonal antibodies intended for outpatient treatment of symptomatic COVID-19 patients in response to the high transmission and significant fatality rates.


Oncology Therapeutic Drug Monitoring Market Regional Analysis

North American market is expected to witness the highest market share during the forecast period due to the well-established healthcare infrastructure. Furthermore, over the projected period, increased government support for cancer research and technology development is expected to stimulate the development of therapeutic proteins. Other major factors assisting the expansion of the industry are government assistance for infection control and management, the rising incidence of lifestyle-related disorders, and the growing population.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

FEATURES OF THE REPORT

  • The Oncology Therapeutic Drug Monitoring Market report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Oncology Therapeutic Drug Monitoring Market report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Oncology Therapeutic Drug Monitoring Market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Oncology Therapeutic Drug Monitoring Market report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Oncology Therapeutic Drug Monitoring Market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Oncology Therapeutic Drug Monitoring Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary
2. Global Oncology Therapeutic Drug Monitoring Market Introduction
2.1. Global Oncology Therapeutic Drug Monitoring Market – Taxonomy
2.2. Global Oncology Therapeutic Drug Monitoring Market –Definitions
2.2.1. Monoclonal Antibody Type
2.2.2. Technology Type
2.2.3. Region
3. Global Oncology Therapeutic Drug Monitoring Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Oncology Therapeutic Drug Monitoring Market Dynamic Factors – Impact Analysis
3.6. New Monoclonal Antibody Monitoring Test Launches
3.7. Mergers and Acquisitions
4. Global Oncology Therapeutic Drug Monitoring Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Oncology Therapeutic Drug Monitoring Market, By Monoclonal Antibody Type, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Infliximab (IFX)
5.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Adalimumab (ADL)
5.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Vedolizumab (VDL)
5.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Ustekinumab (UTK)
5.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Golimumab (GLM)
5.5.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Etanercept (ETN)
5.6.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Rituximab (RTX)
5.7.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Tocilizumab (TCZ)
5.8.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
6. Global Oncology Therapeutic Drug Monitoring Market Forecast, By Technology, 2017- 2021 and Forecast, 2022 – 2028
6.1. Immunoassay
6.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Others
6.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Oncology Therapeutic Drug Monitoring Market Forecast, By Region, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. EMEA (Europe, Middle East and Africa)
7.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Global Oncology Therapeutic Drug Monitoring Market – Opportunity Analysis Index, By Monoclonal Antibody Type, Technology Type, and Region, 2022 – 2028
8. North America Oncology Therapeutic Drug Monitoring Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. Monoclonal Antibody Type Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Infliximab (IFX)
8.1.2. Adalimumab (ADL)
8.1.3. Vedolizumab (VDL)
8.1.4. Ustekinumab (UTK)
8.1.5. Golimumab (GLM)
8.1.6. Etanercept (ETN)
8.1.7. Rituximab (RTX)
8.1.8. Tocilizumab (TCZ)
8.2. Technology Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Immunoassay
8.2.2. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Oncology Therapeutic Drug Monitoring Market – Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2022 – 2028
8.5. North America Oncology Therapeutic Drug Monitoring Market Dynamics – Trends
9. EMEA Oncology Therapeutic Drug Monitoring Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Monoclonal Antibody Type Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Infliximab (IFX)
9.1.2. Adalimumab (ADL)
9.1.3. Vedolizumab (VDL)
9.1.4. Ustekinumab (UTK)
9.1.5. Golimumab (GLM)
9.1.6. Etanercept (ETN)
9.1.7. Rituximab (RTX)
9.1.8. Tocilizumab (TCZ)
9.2. Technology Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Immunoassay
9.2.2. Others
9.3. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. Spain
9.3.4. Italy
9.3.5. France
9.3.6. Saudi Arabia
9.3.7. Rest of EMEA
9.4. EMEA Oncology Therapeutic Drug Monitoring Market – Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2022 – 2028
9.5. EMEA Oncology Therapeutic Drug Monitoring Market Dynamics – Trends
10. Asia-Pacific Oncology Therapeutic Drug Monitoring Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Monoclonal Antibody Type Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Infliximab (IFX)
10.1.2. Adalimumab (ADL)
10.1.3. Vedolizumab (VDL)
10.1.4. Ustekinumab (UTK)
10.1.5. Golimumab (GLM)
10.1.6. Etanercept (ETN)
10.1.7. Rituximab (RTX)
10.1.8. Tocilizumab (TCZ)
10.2. Technology Analysis, 2017 – 2017 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Immunoassay
10.2.2. Others
10.3. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. Rest of Asia-Pacific
10.4. Asia-Pacific Oncology Therapeutic Drug Monitoring Market – Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2022 – 2028
10.5. Asia-Pacific Oncology Therapeutic Drug Monitoring Market Dynamics – Trends
11. Latin America Oncology Therapeutic Drug Monitoring Market Analysis,  2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Monoclonal Antibody Type Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Infliximab (IFX)
11.1.2. Adalimumab (ADL)
11.1.3. Vedolizumab (VDL)
11.1.4. Ustekinumab (UTK)
11.1.5. Golimumab (GLM)
11.1.6. Etanercept (ETN)
11.1.7. Rituximab (RTX)
11.1.8. Tocilizumab (TCZ)
11.2. Technology Analysis, 2017 – 2017 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Immunoassay
11.2.2. Others
11.3. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Latin America Oncology Therapeutic Drug Monitoring Market – Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2022 – 2028
11.5. Latin America Oncology Therapeutic Drug Monitoring Market Dynamics – Trends
12. Competition Landscape 
12.1. Strategic Dashboard of Top Market Players
12.2. Company Profiles (Introduction, Financial Analysis, Monoclonal Antibody Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
12.2.1. Grifols, S.A.
12.2.2. Miraca Life Sciences
12.2.3. Prometheus Laboratories Inc.
12.2.4. R-biopharm
12.2.5. BÜHLMANN
13. Research Methodology
14. Key Assumptions and Acronyms

Report

Company Profile

  • Grifols, S.A.
  • Miraca Life Sciences
  • Prometheus Laboratories Inc.
  • R-biopharm
  • BÜHLMANN

Description

Oncology Therapeutic Drug Monitoring Market size is valued at USD x million in 2021 and is expected to reach a value of USD x million by 2028, growing at a CAGR of x% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Oncology Therapeutic Drug Monitoring Market and that can be segmented by monoclonal antibody type, and technology type. By monoclonal antibody type, the Oncology Therapeutic Drug Monitoring Market has been segmented into infliximab (IFX), adalimumab (ADL), vedolizumab (VDL), ustekinumab (UTK), golimumab (GLM), Etanercept (ETN), rituximab (RTX), tocilizumab (TCZ)). The golimumab (GLM)segment is likely to be the largest and fastest-growing segment in terms of monoclonal antibody type. Based on technology type, the Oncology Therapeutic Drug Monitoring Market is segmented into immunoassay and others.  Among these, the immunoassay segment is expected to have the fastest-growing market during the forecast period 2022-2028.

Key Developments:

In July 2021, Roche announced the approval of “Ronapreve” (casirivimab and indevimab) for intravenous infusion treatment of patients with mild to moderate COVID-19. Under Article 14-3 of the Pharmaceuticals and Medical Devices Act, the antibody combination received Special Approval.

Reviews

There are no reviews yet.

Be the first to review “Oncology Therapeutic Drug Monitoring Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX